Protection mechanisms against Aβ42 aggregation

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 548-554

  Yan, Y ^a   Wang, C ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

A 40; A 42 aggregation; Alzheimer's disease (AD); Amyloid peptide (A ); Heat shock protein; Heme; Insulin degrading enzyme (IDE); L PGDS; Matrix metalloprotease (MMP); Methionine oxidation; Neprilysin (NEP); NMR; Protection

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; HEAT SHOCK PROTEIN; HEME; INSULINASE; LIPOCALIN TYPE PROSTAGLANDIN D SYNTHASE; MATRIX METALLOPROTEINASE; MEMBRANE METALLOENDOPEPTIDASE; METHIONINE; METHIONINE 35; OLIGOMER; PROSTAGLANDIN D SYNTHASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); NERVE PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; DEMENTIA; HUMAN; NERVE CELL NECROSIS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 58049216775     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898460     Document Type: Review

References (100)

1. Mikiciuk-Olasik E, Szymanski P and Zurek E. Diagnostics and therapy of Alzheimer's disease. Indian J Exp Biol 45(4): 315-25 (2007).
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2): 741-66 (2001).
3. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
4. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5): 1005-13 (1996).
5. Citron, M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3(1): 67-72 (1997).
6. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602): 710-3 (1996).
7. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2(8): 864-70 (1996).
8. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267(1): 546-54 (1992).
9. Jarrett JT, Berger EP and Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 695: 144-8 (1993).
10. Jarrett JT, Berger EP and Lansbury JrPT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32(18): 4693-7 (1993).
11. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95(3): 834-47 (2005).
12. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8(1): 79-84 (2005).
13. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 4(2): 119-25 (1997).
14. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19(20): 8876-84 (1999).
15. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95(11): 6448-53 (1998).
16. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440(7082): 352-7 (2006).
17. Lorenzo A and Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91(25): 12243-7 (1994).
18. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, et al. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 102(48): 17342-7 (2005).
19. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13(4): 1676-87 (1993).
20. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271(34): 20631-5 (1996).
21. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572(Pt 2): 477-92 (2006).
22. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-9 (2002).
23. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271(8): 4077-81 (1996).
24. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6): 860-6 (1999).
25. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1): 106-13 (2008).
26. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11): 2866-75 (2007).
27. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-42 (2008).
28. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41(5): 345-52 (2002).
29. Cheng, I.H., Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282(33): 23818-28 (2007).
30. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451(7179): 720-4 (2008).
31. Yan Y and Wang C. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 369(4): 909-16 (2007).
32. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47(2): 191-9 (2005).
33. Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interaction between A beta (1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 38(47): 15514-21 (1999).
34. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27(3): 627-33 (2007).
35. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67(3): 1216-28 (1994).
36. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, et al. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87(3): 609-19 (2003).
37. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22(12): 4833-41 (2002).
38. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96(3): 732-42 (2006).
39. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27(7): 686-95 (2006).
40. Shen J and Kelleher RJ. 3rd, The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104(2): 403-9 (2007).
41. Deng Y, Tarassishin L, Kallhoff V, Peethumnongsin E, Wu L, Li YM, et al. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. J Neurosci 26(14): 3845-54 (2006).
42. Walter S and Buchner J. Molecular chaperones--cellular machines for protein folding. Angew Chem Int Ed Engl 41(7): 1098-113 (2002).
43. Wilhelmus MM, de Waal RM and Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol 35(3): 203-16 (2007).
44. Gusev NB, Bogatcheva NV and Marston SB. Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Mosc) 67(5): 511-9 (2002).
45. de Jong WW, Caspers GJ and Leunissen JA. Genealogy of the alpha-crystallin - small heat-shock protein superfamily. Int J Biol Macromol 22(3-4): 151-62 (1998).
46. Yokota T, Mishra M, Akatsu H, Tani Y, Miyauchi T, Yamamoto T, et al. Brain site-specific gene expression analysis in Alzheimer's disease patients. Eur J Clin Invest 36(11): 820-30 (2006).
47. Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, de Jong WW. The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 8(1): 53-61 (2003).
48. Wilhelmus MM, Otte-Höller I, Wesseling P, de Waal RM, Boelens WC, Verbeek MM. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol Appl Neurobiol 32(2): 119-30 (2006).
49. Wilhelmus MM, Boelens WC, Otte-Höller I, Kamps B, Kusters B, Maat-Schieman ML, et al. Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol 111(2): 139-49 (2006).
50. Wilhelmus MM, Boelens WC, Otte-Höller I, Kamps B, de Waal RM, Verbeek MM, et al. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res 1089(1): 67-78 (2006).
51. Narayanan S, Kamps B, Boelens WC, Reif B. AlphaB-crystallin competes with Alzheimer's disease beta-amyloid peptide for peptide-peptide interactions and induces oxidation of Abeta-Met35. FEBS Lett 580(25): 5941-6 (2006).
52. Shimura H, Miura-Shimura Y and Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279(17): 17957-62 (2004).
53. Renkawek K, Bosman GJ and de Jong WW, Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol 87(5): 511-9 (1994).
54. Renkawek K, Bosman GJ and Gaestel M. Increased expression of heat-shock protein 27 kDa in Alzheimer disease: a preliminary study. Neuroreport 5(1): 14-6 (1993).
55. Nardai G, Csermely P and Soti C. Chaperone function and chaperone overload in the aged. A preliminary analysis. Exp Gerontol 37(10-11): 1257-62 (2002).
56. Csermely P. Chaperone overload is a possible contributor to 'civilization diseases'. Trends Genet 17(12): 701-4 (2001).
57. Urade Y and Hayaishi O. Biochemical, structural, genetic, physiological and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 1482(1-2): 259-71 (2000).
58. Urade Y and Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 58: 89-120 (2000).
59. Ujihara M, Urade Y, Eguchi N, Hayashi H, Ikai K, Hayaishi O. Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. Arch Biochem Biophys 260(2): 521-31 (1988).
60. Urade Y, Fujimoto N, Kaneko T, Konishi A, Mizuno N, Hayaishi O. Postnatal changes in the localization of prostaglandin D synthetase from neurons to oligodendrocytes in the rat brain. J Biol Chem 262(31): 15132-6 (1987).
61. Yamashima T, Sakuda K, Tohma Y, Yamashita J, Oda H, Irikura D, et al. Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci 17(7): 2376-82 (1997).
62. Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, Okazaki I, et al. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci USA 104(15): 6412-7 (2007).
63. Harrington MG, Aebersold R, Martin BM, Merril CR, Hood L. Identification of a brain-specific human cerebrospinal fluid glycoprotein, beta-trace protein. Appl Theor Electrophor 3(5): 229-34 (1993).
64. Saso L, Leone MG, Sorrentino C, Giacomelli S, Silvestrini B, Grima J, et al. Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor. Biochem Mol Biol Int 46(4): 643-56 (1998).
65. Howlett D, Cutler P, Heales S, Camilleri P. Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Lett 417(2): 249-51 (1997).
66. Atamna H and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci USA 103(9): 3381-6 (2006).
67. Atamna H and Frey WH. 2nd, A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA 101(30): 11153-8 (2004).
68. Atamna H. Heme binding to Amyloid-beta peptide: mechanistic role in Alzheimer's disease. J Alzheimers Dis 10(2-3): 255-66 (2006).
69. Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20(3): 325-30; discussion 339-42 (1999).
70. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276(16): 12991-8 (2001).
71. Hou L, Kang I, Marchant RE, Zagorski MG. Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. J Biol Chem 277(43): 40173-6 (2002).
72. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, et al. A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. J Am Chem Soc 125(50): 15359-65 (2003).
73. Johansson AS, Bergquist J, Volbracht C, Päiviö A, Leist M, Lannfelt L, et al. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport 18(6): 559-63 (2007).
74. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, et al. Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 126(7): 1992-2005 (2004).
75. Yan Y, Liu J, McCallum SA, Yang D, Wang C. Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42. Biochem Biophys Res Commun 362(2): 410-4 (2007).
76. Yan Y and Wang C. Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J Mol Biol 364(5): 853-62 (2006).
77. Yan Y, McCallum S and Wang C. M35 Oxidation Induces Aβ40-like Structrual and Dynamical changes in Aβ42. J Am Chem Soc In press. (2008).
78. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100(7): 4162-7 (2003).
79. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6(2): 143-50 (2000).
80. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 100(10): 6221-6 (2003).
81. Carson JA and Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81(1): 1-8 (2002).
82. Howell S, Nalbantoglu J and Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16(4): 647-52 (1995).
83. Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem 128(6): 897-902 (2000).
84. McDermott JR and Gibson AM. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res 22(1): 49-56 (1997).
85. Perez A, Morelli L, Cresto JC, Castaño EM. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25(2): 247-55 (2000).
86. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273(49): 32730-8 (1998).
87. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 292(5521): 1550-2 (2001).
88. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40(6): 1087-93 (2003).
89. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Ageand region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26(5): 645-54 (2005).
90. Hama E and Saido TC Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65(3): 498-500 (2005).
91. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp Gerontol 35(9-10): 1317-25 (2000).
92. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18(2): 240-52 (2008).
93. Backstrom JR, Lim GP, Cullen MJ, Tökés ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16(24): 7910-9 (1996).
94. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281(34): 24566-74 (2006).
95. Asahina M, Yoshiyama Y and Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20(2): 60-3 (2001).
96. Deb S, Zhang JW and Gottschall PE. Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to beta-amyloid peptide. J Neurosci Res 55(1): 44-53 (1999).
97. Jung SS, Zhang W and Van Nostrand WE. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 85(5): 1208-15 (2003).
98. Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 54(3): 379-82 (2003).
99. Backstrom JR, Miller CA and Tokes ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 58(3): 983-92 (1992).
100. Guo S, Wang S, Kim WJ, Lee SR, Frosch MP, Bacskai BJ, et al. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res 1111(1): 222-6 (2006). ??